Longeveron up on publication of early-stage trial results for Alzheimer's drug
31/03/2022 16:09
** Shares of biopharma company LGVN.O jumps 39.0% to $9.34
** Co publishes peer reviewed study of Phase 1 trial results
of its key drug Lomecel-B for Alzheimer's urn:newsml:reuters.com:*:nFWN2VY0SO
** Trial met its primary endpoint, demonstrating Lomecel-B
was well tolerated in this patient population - co
** More than 38 mln shares traded so far, ~43.5 times their
25-day moving avg
** LGVN is third most trending stock on retail
investor-focused forum Stocktwits.com
** It is also among 10 most ordered stocks, according to
Fidelity Research, as of 10:32 AM ET
** Both brokerages covering LGVN rate stock "buy"; their
median PT is $20 - Refinitiv data
** Stock has fallen ~22.6% YTD
(Reporting by Bansari Mayur Kamdar in Bengaluru)
((BansariMayur.Kamdar@thomsonreuters.com;))